Learners will enhance their knowledge on candidate guideline recommendation/s from the release of the 2022 AHA/American College of Cardiology/Heart Failure Society of America guideline for managing Heart Failure. This activity will also cover the latest clinical findings on the effects of new SGLT2 inhibitors such as ertugliflozin, licogliflozin (LIK066), henagliflozin, bexagliflozin, and sotagliflozin on the Stage A Heart Failure and Metabolic Syndrome Outcomes in individuals without DM, HF, and/or CKD.
- Provider:American College of Clinical Pharmacology
- Activity Link: https://accp1.org/cpsso/sso.aspx?returl=https://ce.accp1.org/products/2023-accp-journal-of-clinical-pharmacology-journal-ce-monthly-ce-offerings
- Start Date: 2023-12-01 06:00:00
- End Date: 2023-12-01 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
- Commercial Support: No
- Activity Type: Journal-based CE
- CME Finder Type: Other
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest